Risk Factors Update Summary

• Accumulated deficit increased from $197 million to $299 million, with net losses each year.
• Capital market conditions have increased borrowing rates, significantly raising the cost of capital.
• Cash, cash equivalents, and marketable securities increased from $317 million to $372 million.
• Recent global events, like supply chain constraints, may lead to higher inflation, impacting product development. This could significantly increase our borrowing rates, raising capital costs compared to prior periods.
• The company is currently litigating a class action complaint in the U.S. District Court.
• Number of full-time employees increased from 137 to 158, impacting operations and development.
• Global conflicts may disrupt clinical trials and manufacturing, affecting our ability to find materials.
• Changes in global political conditions, such as elections and geopolitical events, could impact operations.
• The company has increased the number of shares of common stock outstanding from 299 to 314 million.
• The number of shares of common stock outstanding has increased from 61 to 90 million.